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Abstract
Background: The objective of the current study was to compare the efficacy
of two different insulin formulations, insulin aspart (IAsp) and regular human
insulin (RHI), for prandial insulin coverage with neutral protamine Hagedorn
(NPH) insulin as basal insulin using a meta-analysis approach. The primary
endpoint was change in A1c over time. Secondary endpoints included inci-
dence of hypoglycemia and postprandial glycemic control.
Methods: Clinical trials (Type 1 and Type 2 diabetes) complying with Good
Clinical Practice, and with individual patient data, were included in the meta-
analysis. Trials were randomized, consisting of (at least) two treatment arms
and had a minimum duration of 12 weeks. Estimates were calculated using
fixed-effects and random-effects models. Heterogeneity was assessed for each
analysis. The effect of baseline parameters on A1c was analyzed in extended
simultaneous models.
Results: The mean difference in A1c was 0.1% (95% confidence interval [CI]
[−0.15; −0.04], P < 0.001) in favor of IAsp. Higher accumulated dose of IAsp,
higher age and increased rates of hypoglycemia were associated with
improved A1c outcome. Fasting plasma glucose was not significantly different
between regimens. Postprandial glucose was significantly lower after treat-
ment with IAsp compared with RHI, but the analysis did present a significant
level of heterogeneity (P < 0.001). The overall rate of hypoglycemia was the
same with both regimens, but nocturnal hypoglycemia was significantly lower
with IAsp.
Conclusions: A basal–bolus regimen with IAsp as bolus insulin provided
minimal, but statistically significant, improvement in overall glycemic control
with a lower rate of nocturnal hypoglycemic episodes, compared with a cor-
responding regimen with bolus RHI.
Keywords: human blood A1c protein, hypoglycemia, insulin aspart, regular
human insulin, meta-analysis.
Significant findings of the study: After 12 weeks of treatment, IAsp + NPH significantly reduced mean HbA1c,
prandial blood glucose increment and the risk for nocturnal hypoglycemia, compared with RHI + NPH.
What this study adds: Our findings reveal that IAsp + NPH demonstrates minimal glycemic control improvement
versus RHI + NPH; its main benefit is in reducing the nocturnal hypoglycemia risk by about 25%, a finding rarely
reported in systematic reviews and meta-analyses.
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Introduction
In people with diabetes, insulin aspart (IAsp)
(NovoRapid, Novo Nordisk, Denmark) is more rapidly
absorbed than regular human insulin (RHI), with higher
maximal concentration and shorter time to peak
concentration.1–3 However, total absorption, the area
under the concentration–time curve, is similar for IAsp
and RHI. Glucose-clamp studies have confirmed that the
reported pharmacokinetic profile for IAsp also reflects
differences in pharmacodynamic activity, showing a sig-
nificantly greater and faster glucose-lowering effect com-
pared with RHI.1–3 IAsp has been extensively studied in
clinical trials as the bolus insulin in basal–bolus regimens
and has consistently shown improved postprandial gly-
cemic control compared with RHI in both Type 1 and
Type 2 diabetes.4–7 In some of these studies, a small but
statistically significant difference in A1c was found in
favor of IAsp,3 whereas in other studies, A1c levels were
comparable.4–7
The aim of this meta-analysis was to compare IAsp
with RHI, both used as bolus insulin in basal–bolus
therapy, with respect to glycemic control. Neutral
protamine Hagedorn (NPH) insulin was used as the
basal component in both regimens. The primary end-
point of this analysis was long-term glycemic control, as
measured by change in A1c over time. Secondary end-
points included incidence of hypoglycemia and post-
prandial glycemic control.
Methods
Trial selection
This retrospective meta-analysis was performed accord-
ing to the guidelines of Whitehead8 and The Cochrane
Policy Manual.9 Trials were considered for inclusion if
they complied with Good Clinical Practice guidelines (in
order to limit heterogeneity and ensure quality of data),
demonstrated methodological quality, included IAsp in
one of the treatment arms and had individual patient
data available. Seventy-eight trials fulfilled the above
conditions, of which, 10 trials satisfied the inclusion and
exclusion criteria listed below and were therefore
included in the final analysis.
Inclusion criteria:
1. Randomized and controlled trials.
2. Trials had to consist of (at least) two arms with IAsp
and RHI, respectively, as bolus insulin, and with NPH as
the intermediate-acting basal insulin in both arms.
3. Trials had to have a treatment period of at least
12 weeks. This period was chosen to collect meaningful
data on efficacy for the primary endpoint.
Exclusion criteria:
1. Trials with pregnant women or children (<18 years).
Two trials had a crossover design; from these studies,
only data from the first treatment period were included
in the meta-analysis. Five of the included studies have
been published.5,10,11–13
Statistical methods
Estimates of the treatment effects were calculated for
every trial included in the meta-analysis. These estimates
were combined into overall estimates using a fixed-effects
model (in which the estimates of the individual trials are
considered similar enough to assume that they are all
estimates of a common treatment effect) and a random-
effects model (in which individual trial estimates are
treated as independent samples from a normal distribu-
tion) to account for heterogeneity. A fixed-effects model
may be considered an implausible oversimplification,14
whereas a random-effects model is considered to be more
complex, realistic and conservative.15 Heterogeneity was
measured using the weighted sum of squares test, thus it
was assumed that the treatment effects were distributed
homogenously; that is, the difference between each treat-
ment effect estimate and the overall treatment effect esti-
mate were normally distributed. Values were estimated
using the intention-to-treat population of each trial.
Efficacy analyses
The primary endpoint was the change in A1c over time.
In the A1c analysis, the possible influence of predictors
such as treatment, demographic characteristics, insulin
dose, age and incidence of hypoglycemic episodes were
evaluated. Secondary endpoints included change in
fasting blood glucose (FBG) and change in postprandial
blood glucose (PPG).
A1c analysis – per-trial model
A1c was measured repeatedly over time and analyzed in
a linear mixed model. The time trends were estimated
separately for the two treatment arms using all available
measurements. Since different time trends would be
expected before and after week 12,16,17 the time trend was
modeled as a linear spline with a knot at week 12. The
treatment effect arising from the difference between these
two splines depended on the reporting time points; we
chose to report the result of the analysis at both week 12
and week 24. In addition to the time trend, the model
included baseline A1c (corresponding to the intercept)
and random slopes (before and after week 12) for each
subject. Given the limited amount of data, a simple cova-
riance structure of the two random slopes was used,
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assuming that they had different variance and were
uncorrelated.
A1c analysis – simultaneous models
A simple simultaneous model was constructed by extend-
ing the per-trial model and pooling all trial data. The
model included the interaction of trial and time, and used
an unstructured covariance of the two random slopes,
allowing correlation between them. An extended simulta-
neous model was also constructed by incorporating
several covariates into the simple simultaneous model;
these included accumulated bolus insulin dose (daily dose
× days of treatment), age, body mass index, diabetes
duration and frequency of hypoglycemic episodes. Trials
066, 1266 and 1634 were excluded from the simultaneous
model as they did not have repeatedmeasurements ofA1c
and therefore did not fit the meta-analysis framework.
Fasting blood glucose
As for A1c, analyses for FBG were performed using a
spline with a knot at week 12 and results were reported at
12 and 24 weeks. Given the limited amount of data, this
analysis was supplemented with an analysis using only
one linear trend, reported at week 16.
Postprandial blood glucose
Postprandial blood glucose was calculated as the mean
of the post-meal measurements (90 min after each meal)
after breakfast, lunch and dinner. PPG increment was
the corresponding mean difference between pre- and
post-meal blood glucose.
Insulin dose
No formal statistical analysis was undertaken specifically
for insulin dose or change in insulin dose during treat-
ment. However, in the extended A1c model, the relation-
ship between A1c and accumulated bolus insulin dose
was reported.
Safety analyses
Safety analyses were limited to hypoglycemic episodes.
The number of hypoglycemic episodes was modeled
using a negative binomial regression model. Effect esti-
mates were calculated as rate ratios: the rate of hypogly-
cemic episodes for patients treated with IAsp relative to
the rate of episodes for patients treated with RHI. The
model was run separately for each trial, and the overall
fixed-effects and random-effects estimates were calcu-
lated. Episodes were only included in the analyses if they
were considered treatment-emergent that is, if they
occurred on or between the dates of the first and the last
doses. Hypoglycemic episodes were classified into three
groups: major, minor and symptoms-only (episodes not
falling within any of the three categories were “unclassi-
fied”). The term “all” was used to denote all hypoglyce-
mic episodes. The term “major” was used for any episode
in which the subject was unable to treat him- or herself.
Episodes handled by the subjects themselves were classi-
fied as “minor” when confirmed by blood glucose mea-
surements <2.8 mmol/L, and as “symptoms-only” when
blood glucose was ≥2.8 mmol/L or the measurement was
missing. In some trials, glucose measurements were
reported as blood glucose, while, in others, they were
reported as plasma glucose. All values presented here
were converted to blood glucose. Nocturnal hypoglyce-
mic episodes were defined as hypoglycemic episodes
occurring in the time interval 00.00 h to 06.00 h, inclu-
sive. Nocturnal episodes were only analyzed within the
“all” class of episodes.
Hypoglycemia data from one trial (054) were not
included in the safety analyses as it did not provide rel-
evant information with regard to the classification of
episodes, measures of blood glucose and whether the
subject was able to treat him- or herself.
Results
The analysis included 10 trials, eight parallel-design and
two crossover trials, conducted in subjects with Type 1
diabetes (six trials), Type 2 diabetes (three trials) or both
types (one trial). Most of the trials were multinational
(7/10). Trial characteristics are presented in Table 1.
Efficacy analyses
The 12-week analysis results for A1c (per-trial model,
excluding trial 066) are shown in Fig. 1. The overall esti-
mate for A1c was significantly lower with IAsp com-
pared with RHI, although the difference was small
(−0.07%, 95% confidence interval [CI] [–0.12%; –0.02%];
P = 0.005); heterogeneity was low (P = 0.730), and the
estimates achieved with the fixed-effects and the random-
effects models were identical. The overall estimate for
A1c after 24 weeks was similar (–0.11%, 95% CI,
[–0.17%; –0.06%]; P < 0.001) and also presented low het-
erogeneity (P = 0.952). In trial 066, HbA1c was measured
only at baseline and after 16 weeks; therefore, it was not
included in the efficacy analysis.
Simultaneous A1c analysis model
The simple simultaneous model (excluding trials 066,
1634 and 1266, as they did not have repeated measure-
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ments of A1c) yielded a similar overall estimate (–0.1%,
95% CI [–0.15; –0.04]; P < 0.001) as the per-trial model.
The decrease in A1c occurred primarily in the first
12-week period (data not shown). Adding baseline A1c
values to the model did not affect the overall treatment
difference estimates, but confirmed that glycemic
improvement occurred shortly after starting treatment
(Table 2). An inter-subject difference of 1% at baseline
would have been reduced to 0.76% after 12 weeks of
treatment, and after an additional 12 weeks to 0.74%.
Thus, beyond the first 12 weeks of treatment, the influ-
ence of baseline A1c level on the decrease in A1c over
time was very small.
The estimates derived from the extended simultaneous
model are shown in the lower part of Table 2. The accu-
mulated dose of IAsp and the accumulated bolus dose
difference (IAsp−RHI) were both significant predictors
for change in A1c, suggesting that increasing the IAsp
dose (in absolute terms or relative to RHI) would predict
an increased difference between regimens and a decrease
in A1c. The accumulated dose of NPH was not a signifi-
cant predictor for change in A1c (data not shown). When
accumulated dose is included in the model, the effect of
treatment is no longer significant, as “accumulated dose”
includes the interaction with time. As may be expected, a
rise in the number of hypoglycemic episodes corre-
sponded to a further lowering of A1c. Age alone was
found to be a significant A1c predictor; that is, the older
the person was at baseline, the more A1c was likely to
improve during treatment. The addition of age and accu-
mulated hypoglycemic episodes (number of episodes
from baseline) to the model had very little, if any, impact
on the effect of baseline A1c. Similar results were
obtained when all 10 trials were included in the extended
model (data not shown).
Fasting blood glucose
Fasting blood glucose was inconsistently reported in the
selected trials; only six trials had relevant data before and
after week 12. No significant treatment difference was
detected in the analysis, either at week 12 or at week 24,
but heterogeneity was high (P = 0.013). Similar results
were obtained when the analysis was repeated for the
16-week treatment period with inclusion of data from all
10 trials.
Postprandial blood glucose
Only the 16-week collection period provided relevant
data for the meta-analysis of PPG. A significant differ-
ence was reported between regimens in favor of IAsp,
with overall estimates of –0.41 mmol/L (95% CI [–0.48;
–0.35]; P < 0.001) and –0.47 mmol/L (95% CI [–0.70;Ta
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Figure 1 Change in A1c (%): per-trial and overall analysis of treatment difference at week 12.
[Correction added on 7 June 2013, after first online publication: The last two P-values have been corrected from 0.01 to 0.005.]
Table 2 Change in A1c (%): simultaneous models*
Factors Period
Estimated change
in A1c (95% CI) P-value
Simple model
Treatment 12 weeks −0.10 [−0.15; −0.04] <0.001
Treatment 24 weeks −0.10 [−0.15; −0.04] <0.001
Simple model plus A1c at baseline
Treatment 12 weeks −0.10 [−0.15; −0.04] <0.001
Treatment 24 weeks −0.10 [−0.15; −0.05] <0.001
Baseline A1c (per 1% difference) 12 weeks 0.76 [0.73; 0.78] <0.001
Baseline A1c (per 1% difference) 24 weeks 0.74 [0.71; 0.76] <0.001
Extended model†
Treatment 12 weeks −0.04 [−0.11; 0.04] 0.333
Treatment 24 weeks 0.02 [−0.08; 0.13] 0.696
Baseline A1c (per 1% difference) 12 weeks 0.76 [0.73; 0.78] <0.001
Baseline A1c (per 1% difference) 24 weeks 0.74 [0.72; 0.76] <0.001
Accumulated IAsp (per 50 U/Kg) −0.09 [−0.14; −0.05] <0.001
Accumulated difference (IAsp–RHI) −0.09 [−0.15; −0.02] 0.007
Age (per 10 years) 12 weeks −0.03 [−0.06; −0.01] 0.006
Age (per 10 years) 24 weeks −0.05 [−0.07; −0.03] <0.001
Hypoglycemia (per 10 episodes) −0.02 [−0.03; −0.01] <0.001
*Excluding trials 066, 1266 and 1634.
†Accounting for effect of HbA1c at baseline, accumulated bolus dose, age and hypoglycemic episodes.
IAsp, insulin aspart; RHI, regular human insulin.
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–0.25]; P < 0.001) using the fixed-effects and the random-
effects analysis models, respectively (Fig. 2). Given the
significant level of heterogeneity within this dataset
(P < 0.001), the random-effects model estimate was con-
sidered more appropriate and, in this case, still demon-
strated a significant difference between regimens. The
analysis of the average change in PPG increment gave
similar results. The difference between regimens was sig-
nificant in favor of IAsp and, although the dataset was
heterogeneous (P ≤ 0.001), both models showed signifi-
cant differences with a fixed-effects estimate of
–0.45 mmol/L (95% CI [–0.51; –0.38]; P < 0.001) and a
random-effects estimate of –0.61 mmol/L (95% CI
[–0.88; –0.34]; P < 0.001).
Safety analyses
The rate of “all” hypoglycemic episodes varied widely
between trials. In general, the rate of hypoglycemia was
higher in subjects with Type 1 diabetes compared with
those with Type 2 diabetes (Table 3). This difference was
found with all types of episode (major, minor and
symptoms-only; data not shown). The overall (and per-
trial) analysis of “all” hypoglycemic episodes is shown in
Fig. 3. Estimates from the fixed-effects (0.99; 95% CI
[0.90; 1.09], P = 0.813) and random-effects analyses
(1.00; 95% CI [0.86; 1.16], P = 0.970) indicated that the
overall rate of episodes was comparable for the two regi-
mens, although the data were heterogeneous (P = 0.055).
A separate analysis made for diurnal episodes showed a
similar trend, with no difference between regimens (data
not shown). By contrast, heterogeneity was low
(P = 0.924) for nocturnal episodes, and the rate of noc-
turnal hypoglycemia was significantly lower with IAsp
compared with RHI (rate ratio for fixed- and random-
effect estimate was 0.76, 95% CI [0.67; 0.85], P < 0.001;
Fig. 4).
Discussion
Previously published meta-analyses comparing the effi-
cacy and safety of rapid-acting insulin analogs with RHI
have consistently shown a modest but statistically signifi-
cant difference in A1c in patients with Type 1 or Type 2
diabetes, in favor of rapid-acting analogs.18–20 These
meta-analyses were based on systematic reviews of pub-
lished trial data. Our meta-analysis was based on data
from randomized controlled trials in patients with Type
1 or Type 2 diabetes that included individual patient
data; to date, only five of the included trials have been
published.5,10,11–13 Our findings confirm that IAsp + NPH
treatment improves overall glycemic control (A1c) and
PPG compared with RHI + NPH treatment. The
improvement in A1c was small and thus clinically of
marginal benefit. By contrast, FBG showed no between-
treatment difference. This was to be expected, as FBG is
mainly controlled by the level of the basal insulin com-
ponent, which was the same for both regimens.
Importantly, improved glycemic control should not be
achieved at the expense of an unacceptable increase in
Figure 2 Change in average blood glucose level (mmol/L) after breakfast, lunch and dinner: per-trial and overall analysis of treatment
differences at week 16.
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the risk for hypoglycemia. Data published from previous
meta-analyses did not reveal differences in overall hypo-
glycemia when comparing rapid-acting analogs and
RHI;20 however, due to a high degree of heterogeneity, it
may have been difficult to draw any firm conclusions.
Our analysis confirmed this finding for overall and
diurnal hypoglycemia. However, heterogeneity was low
for the analysis of nocturnal hypoglycemia, and event
rates were significantly lower with IAsp compared with
RHI. The lower overall incidence of nocturnal hypogly-
cemia with IAsp, as observed in some of the individual
trials and reported with other rapid-acting analogs,21 is
to be expected, as IAsp is eliminated considerably faster
than RHI from circulation. Nonetheless, a reduction in
the rate of nocturnal hypoglycemia, a variable rarely
investigated in systematic reviews, may have important
clinical implications that should not be overlooked.
Studies show that nocturnal hypoglycemia can have a
detrimental effect on health, quality of life and produc-
tivity in patients with Type 1 or Type 2 diabetes.22,23
Patients who experience nocturnal hypoglycemic epi-
sodes report an increase in tiredness, sleeping difficulties
and absenteeism from work. In addition, some patients
reduce their normal insulin dose after an episode, thus
potentially compromising their diabetes management
regimen.24 It is also recognized that patients substantially
fear the recurrence of nocturnal hypoglycemia, which
may reduce their adherence to insulin therapy.23 Further-
more, nocturnal hypoglycemia may also contribute
toward (i) the impaired awareness of future hypoglyce-
mic events, which, in turn, may increase the risk of major
hypoglycemia,25,26 and (ii) terminal conditions, such as
“dead-in-bed” syndrome.27
Most published data, whether from individual trials or
meta-analyses, are based on non-treat-to-target regi-
mens. In these studies, the increase in insulin dose during
treatment was moderate, and the absolute treatment
effect on A1c was small. Our study supports these find-
ings; however, the accumulated dose of IAsp (but not of
RHI) was a significant predictor for A1c, indicating that
an increase in IAsp dose, absolute or relative to RHI,
would predict an increased difference between the
two regimens. In a treat-to-target designed study, up-
titration of IAsp to predetermined glycemic targets may
result in a greater reduction of A1c; however, in turn,
higher doses of IAsp may also increase the risk of hypo-
glycemia. In relative terms, another significant predictor
of A1c was age: the older the person was at baseline, the
more A1c was likely to improve during treatment, inde-
pendent of treatment regimen.
Important limitations of our meta-analysis include the
short duration of most of the trials and that none of them
had a treat-to-target design. The meta-analysis may alsoTa
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Figure 3 Per-trial and overall analysis of all hypoglycemic episodes (rate ratios with 95% confidence intervals).
[Correction added on 7 June 2013, after first online publication: The P-value for ‘Type 1 and Type 2’ has been corrected from 0.01 to 0.005.]
Figure 4 Per-trial and overall analysis of nocturnal hypoglycemic episodes (rate ratios with 95% confidence intervals).
S. HELLER et al. Meta-analysis of insulin regimens
489© 2013 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.
have been confounded by the different study designs/
protocols of the included trials; however, this is an inher-
ent problem of meta-analyses and we have attempted to
account for heterogeneity where possible. In addition, as
the main focus of the study was to compare two different
formulations of bolus insulin, it is possible that the titra-
tion of basal insulin was not monitored as robustly as
bolus titration. It remains to be established how the two
treatment regimens would compare in trials of longer
duration and a more aggressive treatment design, in par-
ticular with respect to glycemic control and hypoglyce-
mia, and the relationship between the two. Given a
basal–bolus regimen and a treat-to-target titration algo-
rithm for the basal and meal-related insulin, it might be
possible to fine-tune the total insulin dose according to
individual characteristics, such as stage of disease, age
and level of physical activity. Therefore, it might be pos-
sible to maximize the different pharmacokinetic and
pharmacodynamic properties of IAsp, through dose
optimization, to improve glycemic control while mini-
mizing the risk of hypoglycemia.
In conclusion, this meta-analysis shows that IAsp used
in combination with NPH insulin provides a minimal but
statistically significant improvement in glycemic control
compared with RHI and NPH. Furthermore, IAsp was
significantly associated with a clinically meaningful and
statistically significant reduction in nocturnal hypoglyce-
mia – a variable not often reported in systematic reviews
yet linked with several aspects of diabetes management,
such as treatment adherence, patients’ quality of life and
the overall risk of hypoglycemia.
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